Key Points
- United Therapeutics COO Michael Benkowitz sold 14,440 shares on Feb. 23 at an average price of $472.13, generating $6,817,557.20 in proceeds.
- Benkowitz has executed a string of insider sales since Dec. 22, including multiple large blocks in January and February, totaling roughly $94 million in disclosed transactions.
- UTHR shares opened at $473.43 the day of the report, trade in a 12‑month range of $266.98–$519.99, have a market cap of about $20.39 billion, and carry a consensus analyst price target of $509.50 ("Moderate Buy").
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 14,440 shares of the company's stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $472.13, for a total transaction of $6,817,557.20. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Michael Benkowitz also recently made the following trade(s):
- On Monday, February 9th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $474.65, for a total value of $10,679,625.00.
- On Monday, February 2nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $470.95, for a total value of $10,596,375.00.
- On Tuesday, January 20th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The shares were sold at an average price of $464.66, for a total value of $6,795,652.50.
- On Tuesday, January 20th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The stock was sold at an average price of $464.66, for a total value of $3,659,197.50.
- On Monday, January 26th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $471.91, for a total transaction of $10,617,975.00.
- On Monday, January 12th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $479.51, for a total transaction of $10,788,975.00.
- On Monday, January 5th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The shares were sold at an average price of $487.38, for a total transaction of $3,838,117.50.
- On Monday, January 5th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The stock was sold at an average price of $487.38, for a total transaction of $7,127,932.50.
- On Monday, December 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $502.79, for a total transaction of $11,312,775.00.
- On Monday, December 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $514.35, for a total transaction of $11,572,875.00.
United Therapeutics Stock Down 0.2%
UTHR stock opened at $473.43 on Wednesday. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $519.99. The company has a market cap of $20.39 billion, a PE ratio of 17.94, a price-to-earnings-growth ratio of 2.53 and a beta of 0.85. The business's 50-day simple moving average is $484.23 and its 200 day simple moving average is $443.45.
Hedge Funds Weigh In On United Therapeutics
Institutional investors have recently bought and sold shares of the business. AXQ Capital LP lifted its stake in United Therapeutics by 495.4% in the second quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company's stock valued at $1,117,000 after buying an additional 3,235 shares during the period. AE Wealth Management LLC grew its position in shares of United Therapeutics by 396.3% during the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company's stock worth $1,798,000 after buying an additional 3,424 shares during the period. Great Lakes Advisors LLC increased its stake in shares of United Therapeutics by 194.7% in the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company's stock valued at $1,888,000 after acquiring an additional 2,975 shares during the last quarter. Optimize Financial Inc bought a new stake in shares of United Therapeutics in the 3rd quarter valued at about $444,000. Finally, Simplify Asset Management Inc. acquired a new stake in shares of United Therapeutics in the 3rd quarter valued at approximately $8,351,000. Institutional investors own 94.08% of the company's stock.
Analysts Set New Price Targets
UTHR has been the subject of a number of recent research reports. Wells Fargo & Company upped their target price on United Therapeutics from $414.00 to $423.00 and gave the company an "equal weight" rating in a research note on Thursday, October 30th. Weiss Ratings restated a "buy (b)" rating on shares of United Therapeutics in a research note on Monday, December 29th. UBS Group reiterated a "buy" rating on shares of United Therapeutics in a research report on Tuesday, February 17th. Royal Bank Of Canada increased their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an "outperform" rating in a research report on Thursday, October 30th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a $575.00 price objective on shares of United Therapeutics in a report on Wednesday, November 19th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $509.50.
Check Out Our Latest Stock Report on United Therapeutics
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
